Trevena Inc.
Formerly Parallex Therapeutics, Inc.
Trevena Inc. is listed today as Trevena, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2013 | $60 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jul 2010 | $18 M | No. 1 | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Trevena Inc. chose not to state its revenue in its newest notice of a funding round (May 2013).
SEC Form D · May 2013
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · May 2013
That is all the official record says: Trevena Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Trevena Inc. are on record.
Investors#
17 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Partners Management VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| FL Holding C.V. | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| FLI International, LLC | Other | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Forest Laboratories Holdings Ltd | Company | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Forest Laboratories Inc | Company | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| HealthCare Partners VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| HealthCare Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| HealthCare Ventures VIII, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Nea 12 GP, LLC | Other | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| NEA Partners 12, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| New Enterprise Associates 12, Limited Partnership | Fund or asset manager | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Management Co. V, L.L.C. | Venture capital | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners Entrepreneurs' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners Special Founders' Fund V, L.P. | Venture capital | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Polaris Venture Partners V, L.P. | Venture capital | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 9 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Maxine Gowen | Executive officer | May 2013 |
| Christopher Mirabelli | Director | May 2013 |
| David Solomon | Director | May 2013 |
| Farah Champsi | Director | May 2013 |
| Lonnie Moulder, Jr. | Director | May 2013 |
| Maxine Gowen | Director | May 2013 |
| Robert Garland | Director | May 2013 |
| Terence McGuire | Director | May 2013 |
| Ralph Snyderman | Director | Jul 2010 |
| Robert, Jr. Ruffolo | Director | Jul 2010 |
About
Biopharmaceutical company.
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.